One category of anti-inflammatory therapies approved for moderate to severe HS is TNF-alpha inhibitors such as adalimumab, as well as interleukin-17 (IL-17) inhibitors such as secukinumab and bimekizumab. The gene discussed is IL17A; the disease is histiocytic sarcoma.